Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Asher Mullard. How can gene therapy platforms be scaled up to treat thousands of rare diseases?. // Nature Reviews Drug Discovery. – 2026. – DOI: 10.1038/d41573-026-00179-2. – URL: https://www.nature.com/articles/d41573-026-00179-2
Asher Mullard (2026). How can gene therapy platforms be scaled up to treat thousands of rare diseases?. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00179-2
Asher Mullard. “How can gene therapy platforms be scaled up to treat thousands of rare diseases?.” Nature Reviews Drug Discovery, 2026. doi:10.1038/d41573-026-00179-2.
@article{Mullard2026,
title = {How can gene therapy platforms be scaled up to treat thousands of rare diseases?},
author = {Mullard, Asher},
journal = {Nature Reviews Drug Discovery},
year = {2026},
doi = {10.1038/d41573-026-00179-2},
url = {https://www.nature.com/articles/d41573-026-00179-2}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/s41573-026-01583-4 From hope to adoption: an industry perspective on the maturation of new approach methodologies